Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 4 study of nirogacestat in premenopausal adult women with desmoid tumor/aggressive fibromatosis
NL-OMON60684Phase 4Recruiting
- Sponsor
- SpringWorks Therapeutics
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nirogacestat in aggressive fibromatosis (AF), sponsored by SpringWorks Therapeutics. Primary endpoint: Ovarian function recovery rate of ovarian toxicity treatment-emergent adverse events. Started Dec 2025; status: recruiting.
02
Drugs
nirogacestat
03
Conditions
aggressive fibromatosis (AF)
Beyond the preview
Go deeper on NL-OMON60684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60684.